• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Feasibility and efficacy evaluation of metallic biliary stents eluting gemcitabine and cisplatin for extrahepatic cholangiocarcinoma

    2020-09-23 10:05:00JingBoXiaoJunYongWengYangYangHuGuiLongDengXinJianWan
    World Journal of Gastroenterology 2020年31期

    Jing-Bo Xiao, Jun-Yong Weng, Yang-Yang Hu, Gui-Long Deng, Xin-Jian Wan

    Abstract

    Key words: Extrahepatic cholangiocarcinoma; Drug-eluting stent; Local chemotherapy; Gemcitabine; Cisplatin; Biliary obstruction

    INTRODUCTION

    Cholangiocarcinoma (CCA) accounts for 7%-10% of all primary hepatobiliary malignancies worldwide[1]and has an extremely poor prognosis. CCA is generally categorized as intrahepatic or extrahepatic (ECC) based on the anatomic location, and ECC patients usually present with signs and symptoms of biliary obstruction such as jaundice and acholic stool[2]. Most patients present with advanced disease that is not amenable to surgery, due to a lack of sensitive, specific tumor markers[3]. Thus, intervention with palliative endoscopic biliary drainage is essential to relieve jaundice and prevent cholangitis and hepatic failure and has been shown to improve quality of life[4]. Clinically, biliary stents are widely used as palliative therapy for advanced ECC[5], but the current stents provide only limited effect of biliary drainage and no antitumor activity. Even metal stents may become occluded over time due to tumor overgrowth or ingrowth, tissue hyperplasia, and biliary sludge[6,7], which may result in progressive biliary obstruction and hepatic failure. The local application of chemotherapy drugs can maximize the drug concentration in the tumor microenvironment and reduce adverse reactions associated with systemic exposure and nontarget organ toxicity[8]. Therefore, drug-eluting stents (DESs) may be a promising approach for the treatment of ECC[9].

    To date, several kinds of biliary DESs have been designed and studied for the treatment of ECC. The first generation was paclitaxel-eluting covered metallic stents, and the data showed that they were probably safe but were not more advantageous than drug-free stents[9-12]. Possible causes for these observations might include suboptimal stent design for the biliary anatomy and the weak effect of paclitaxel on ECCs[13]. Other kinds of biliary DESs, such as gemcitabine-eluting, sorafenib-eluting, and vorinostat-eluting stents, have also been reported[14-16]. These new DESs seem to be effective in inhibiting the proliferation of CCA cells; however, all of them are singledrug-loaded stents, and studies on the feasibility and safety of stent placement in the common bile duct (CBD) are lacking.

    The current standard chemotherapeutic regimen for CCA is gemcitabine (GEM) plus cisplatin (CIS)[17-19]. The combination of these two agents has shown improved survivability without substantial toxicity[20,21]. Accordingly, we propose that local chemotherapy with two drugs is feasible and superior to a single drug. Therefore, we designed and fabricated novel GEM and CIS-eluting biliary stents using mixed electrospinning. In this study, we aimed to investigate the drug release property, antitumor activity, and biocompatibilityin vitroandin vivoto evaluate the feasibility and efficacy of this novel stent for ECC.

    MATERIALS AND METHODS

    Fabrication of GEM and CIS-eluting biliary stents

    Stents coated with GEM and CIS-eluting nanofiber membranes were fabricated by the mixed electrospinning method using an electrospinning machine (EBS ES-Biocoater; Nano NC, Seoul, South Korea) (Figure 1A). Poly- L-lactide-caprolactone (PLCL) was used as the drug carrier. The electrospinning solution (10%w/v) was prepared by dissolving 500 mg PLCL in 5 mL hexafluoroisopropanol. Then, different amounts of GEM/CIS (mass ratio 1:1) were added to this solution, and the final drug concentration was adjusted to 0%-20% (w/w) versus PLCL. The nickel-titanium metallic biliary stent (Micro-Tech Co., Ltd., Nanjing, China) covered with a PTFE inner coating membrane was 20 mm in length and 4 mm in diameter when fully expanded. The PTFE membrane was designed as an inner blocker to avoid drug loss of the bile flow and ensure maximum delivery into the tumor tissue. The stent was placed into a rolling collector (diameter 4 mm, length 15 cm, rolling speed 200 rpm, voltage 10 kV), and then 5 mL of the mixed electrospinning solution was transferred into a syringe with a 22G needle and sprayed onto the stent at a speed of 1.5 mL/h. Specifically, one PLCL-unloaded membrane was added to the drug-loaded stents as the outer layer to avoid drug burst release (Figure 1B). We prepared four types of DESs, namely, PLCL-0, PLCL-GEM, PLCL-CIS, and PLCL-GC (Figure 1C) (according to drug components), with different drug-loading ratios (0%, 5%, 10%, 15% and 20% (w/w). Next, the drugcoated stent was carefully isolated from the collector and dried, weighed, and sterilized. For cell experiments and animal studies, different kinds of drugincorporated nanofiber membranes were carefully separated from the stent and stored.

    Characterization of the nanofiber films

    The nanofiber morphology of the samples was observed under a scanning electron microscope (S-4800, Hitachi S-4800, Japan). In addition, to examine the ingredients of the nanofiber, Fourier transform infrared (FTIR) spectra were obtained by the potassium bromide disk method with an Avatar 380 FTIR instrument (Nicolet 6700, Thermo Fisher, United States).

    In vitro drug release studies

    The stents loaded with different drug components and loading ratios were placed into 15 mL centrifuge tubes separately (n= 6 in each group) with 10 mL phosphatebuffered saline (PBS, pH 7.4). Then, the tube was placed in a shaking incubator (HNYC-100D, Zhejiang NADE Scientific Instrument Co., China) at 100 rpm at 37 °C. At specific time intervals (1 d, 2 d, 3 d, 4 d, 5 d, 8 d, 11 d, 14 d, 19 d, 24 d, and 30 d), 1 mL of the media in the tube was taken to measure the released drug by highperformance liquid chromatography, and then an equal volume of fresh PBS was supplemented in each tube for continuous incubation. The cumulative drug release percentage was calculated as the actual cumulative drug release/total drug-loading capacity × 100%.

    Figure 1 Manufacturing and characteristics of different biliary drug-eluting stents. A: Schematic illustration of the manufacturing of drug-eluting stents by the mixed electrospinning method; B: Optimized design of the gemcitabine/cisplatin-eluting biliary stent. The entire structure of the coated membranes consists of three layers: the inner polytetrafluoroethylene membrane (as a blocker to avoid drug loss), the middle PLCL layer (as the major drug carrier), and the outer PLCL-unloaded membrane (as a blocker to prevent burst release); C: Image of different types of drug-eluting stents; D: Fourier transform infrared spectra of different prototype drugs and drug-eluting nanofilms; E: Scanning electron microscope images of different drug-eluting nanofilms (magnification ×2000). CIS: Cisplatin; GEM: Gemcitabine; PLCL: Poly-L-lactide-caprolactone; PLCL-0: Non-drug-loaded PLCL nanofilm; PLCL-CIS: PLCL nanofilm loaded with CIS; PLCL-GEM: PLCL nanofilm loaded with GEM; PLCL-GC: PLCL nanofilm loaded with both GEM and CIS; PTFE: Polytetrafluoroethylene.

    Cell culture

    The EGI-1 ECC cell line was obtained from the DSMZ (German Collection of Microorganisms and Cell Cultures; Braunschweig, Germany) and maintained in Dulbecco's modification of Eagle's medium (DMEM) containing 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin at 37 °C in a 5% CO2incubator.

    Antitumor activity study in vitro

    EGI-1 cells were seeded into 96-well plates at a density of 4000 cells per well overnight in an incubator with 5% CO2at 37 °C. Following incubation, the cells were treated with GEM (0, 0.312, 0.625, 1.25, 2.5, 5, 10, and 20 μg/mL) or CIS (0, 0.312, 0.625, 1.25, 2.5, 5, 10, and 20 μg/mL) or their combinations for 24 h. To evaluate the antitumor activity of released drugs from the nanofiber membrane, a stent sample was immersed in serumfree DMEM into a 15 mL tube and treated as described previously. Drug-released media were collected every 24 hours and added to 96-well plates for incubation with EGI-1 cells. Cell viability after treatment was determined using a Cell Counting Kit 8 assay (Yeasen, Shanghai, China).

    Calcein-AM/propidium iodide double staining

    EGI-1 cells were seeded into a 6-well plate at a density of 1 × 106cells/well and incubated with different kinds of drug-released media for 24 h. Then, the cells were digested, isolated, and costained with calcein-AM for living cells and propidium iodide for dead cells. Images were taken on a Leica DMi8 fluorescence microscope.

    Scratch wound-healing assay

    A scratch wound-healing assay was conducted to evaluate cell migration. After EGI-1 cells grew to form a confluent monolayer in a 6-well plate, a scratch was created along the central line of the well with a micropipette tip. Suspended cells were removed with PBS flushing, and the remaining cells were incubated with different kinds of drugreleased media. Cells were photographed on a light microscope at 48 h.

    Cell migration assay

    In vitrocell migration assays were performed using a transwell chamber (Corning, United States) precoated with Matrigel (BD Biosciences, United States). EGI-1 cells (2 × 104) cultured in serum-free DMEM were seeded into the upper chamber. The lower chamber was filled with GEM/CIS-released media supplemented with 10% FBS. Cells that migrated to the reverse side of the membrane two days later were fixed with 4% paraformaldehyde and stained with Giemsa. The number of cells in 5 randomly selected microscopic fields per membrane was counted in each group.

    In vivo tumor xenograft experiment

    BALB/c nude mice (16-20 g, 4 wk old, male) were obtained from the Experimental Animal Center, Shanghai Jiaotong University. Mice were housed under a 12 h/12 h light/dark cycle at 22 ± 1 °C and 50% humidity and were given a standard chow diet with free access to food and drinking water. One hundred microliters of EGI-1 cells (2 × 106/mouse) were injected subcutaneously into the right flank of each BALB/c mouse. Tumor diameters were measured every two days. When the tumor diameter reached nearly 5 mm, the following drug-eluting PLCL nanofilms were surgically implanted under the tumor: (1) None (nonimplanted group); (2) Empty PLCL nanofilm; (3) GEM-loaded nanofilm; (4) CIS-loaded nanofilm; and (5) GEM and CISloaded nanofilm (n= 6 in each group). Body weight and tumor volume were measured every 2 d after implantation using the formula: Volume = 1/2 × length × width2.

    Histopathological analysis of the tumors

    All the mice were sacrificed 4 wk later, and the tumors were harvested separately for further experiments. The tumor tissues were fixed with 4% paraformaldehyde, embedded in paraffin, and sectioned for hematoxylin and eosin (HE) staining. Additionally, to investigate the possible mechanisms involved, tumor tissues from extra groups of experimental mice were harvested one week after the implantation of drug-loaded nanofilms and subjected to a terminal deoxynucleotidyl transferasemediated dUTP nick end labeling (TUNEL) assay (Abcam, England). Immunohistochemical staining was carried out with a cleaved caspase 3 antibody (CST, United States) at a dilution of 1:500 and an anti-PUMA (p53 upregulated modulator of apoptosis) (Abcam) antibody at a dilution of 1:200. Staining was performed using a Fast Red Substrate Kit (Abcam).

    Stent placement in the CBD

    Twenty-seven healthy Bama minipigs with an average weight of 25.7 ± 3.4 kg (Provided by Shanghai Jiaotong University School of Agriculture and Biology, Shanghai, China) were acclimatized to the following laboratory conditions: 22 ± 1 °C, 12 h/12 h light/dark cycle, 50% humidity and free access to food and drinking water. Pigs were randomly divided into five groups: Group A was sham operated (n= 3), group B received stent PLCL-0 (n= 6), group C received stent PLCL-GEM (n= 6), group D received stent PLCL-CIS (n= 6), and group E received stent PLCL-G&C (n= 6).

    All the animals were fasted for 48 h before stent placement. Anesthesia was induced with an injection of 3% pentobarbital sodium (1 mL/kg) into the auricular vein. The pigs were positioned in a supine position. After a median incision was made in the upper abdomen and the CBD was successfully separated, a small incision was made above the CBD, through which the stent was placed into the CBD. The stent was then fixed on the bile duct wall with a 5.0 suture to avoid stent migration. For percutaneous cholangiography, we inserted a flexible tube cut from a scalp needle into the CBD towards the hepatic duct through the previous incision. Five mL contrast agent was injected into the CBD through the percutaneous tube, and the position of the stent was evaluated. The abdominal cavity was closed after cholangiography.

    Hematologic examination

    Serum samples were collected on day 0 (preoperation), 1, 3, 7, 14 and 28, and the serum white blood cell (WBC) count and alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TBil), γ-glutamyl transpeptidase (γ-GT), amylase and creatinine levels were measured to evaluate hepatorenal function and the inflammatory reaction after stent placement in all pigs.

    Histologic analysis

    All the animals were euthanized 4 wk after stent placement, and tissue samples, including the bile duct, liver, kidney, and duodenum, were harvested for histologic examination. The bile duct was removed from the hepatic bifurcation to the duodenum, including a portion of the duodenum and ampulla. The bile duct was then opened longitudinally, and each stent was gently removed. General morphological changes in the ductal mucosa and stents were evaluated. All the tissues were fixed with 4% paraformaldehyde for 24 h, and then HE staining and Masson trichrome staining were carried out. The thickness of the epithelial layers and the degree of submucosal inflammatory cell infiltration were evaluated in consensus by two experienced pathologists.

    All animal experiments were approved by the Ethics Committee of Shanghai General Hospital.

    Statistical analysis

    All data were analyzed using SPSS version 23.0 (SPSS Inc., Chicago, Illinois, United States). Data are presented as the mean ± standard deviation. Student’sttest was used to compare continuous quantitative data between two groups, while differences between multiple groups were detected by analysis of variance. A two-tailed Wilcoxon signed-rank test was applied for ranked data. APvalue < 0.05 was considered statistically significant.

    RESULTS

    Characteristics of GEM and CIS-eluting biliary stents

    Four different GEM and CIS-loaded nanofilm-covered stents were manufactured by the mixed electrospray method (Figure 1C). As shown in the FTIR spectra (Figure 1D), extra peaks (seen at 3300 cm?1to 3500 cm?1and at 700 cm?1to 1700 cm?1) were observed in the PLCL-GEM, PLCL-CIS, and PLCL-G&C polymers loaded with drugs, while they were absent in the pure PLCL polymer. The fiber morphology characterized by scanning electron microscopy is shown in Figure 1E. Pure PLCL nanofibers were smooth, while drug-loaded polymers were scattered with drug particles of relatively equal sizes. All these results demonstrated successful drug loading into the nanofibers.

    Drug release in vitro

    GEM-loaded nanofibers with different drug-loading ratios exhibited similar release behaviorsin vitro, while nanofibers with a low drug-loading ratio released relatively faster than those with a high drug-loading ratio (Figure 2A). The release of GEM consisted of three phases: The initial rapid release phase (day 0-10, cumulative release for 75% of the total drug-loading amount), the medium-term stable phase (day 11-20, steady and gentle release for 85%), and the late terminal platform phase (day 21-30, nearly complete release for ≥ 95%).

    The release of CIS consisted of two phases: The initial phase (day 0-7, cumulative release for 15%-20%) and the uniform-stable phase (day 8-30, cumulative release for 25%-35%) (Figure 2B). The release of CIS was different from that of GEM. First, nanofibers with a drug-loading ratio of 5% released faster than those with other drugloading ratios, while no significant difference was observed between nanofibers with high drug-loading ratios in the initial phase. Second, a significant gap in the release percentage was observed over time. Third, the total released amount of CIS at the end of the observation period was much lower than that of GEM.

    This difference is mainly due to the different solubilities of GEM and CIS. The solubility of GEM is higher than that of CIS at 37 °C, so it is easier for GEM to be released from PLCL nanofibers. In the first stage, the primary mechanism for drug release is dissolution so that drugs can be released rapidly, especially GEM. In the subsequent phase, a combination of diffusion and degradation become the major forms of drug release; due to the long distance for diffusion from the internal membrane and the relatively slow PLCL degradation rate, the drug release rate during this period gradually slows and can be maintained to a near-constant degree.

    Figure 2 Cumulative drug release of different biliary drug-eluting stents with different drug-loading ratios. A: Release curves of gemcitabine from PLCL-GEM-eluting stents; B: Release curves of cisplatin from PLCL-CIS-eluting stents; C: Release curves of (a) gemcitabine and (b) cisplatin from PLCL-GEM and CIS-eluting stents. CIS: Cisplatin; GEM: Gemcitabine; PLCL: Poly-L-lactide-caprolactone.

    The release of GEM (Figure 2C-a) and CIS (Figure 2C-b) from PLCL-GEM and CIScoloaded nanofibers was similar to the single-drug-loaded nanofibers, albeit with a slightly slower release rate.

    Antitumor activity of PLCL-GEM and CIS nanofilms against EGI-1 cells in vitro

    The antitumor activity of GEM and CIS-loaded nanofilms was assessed by examining the viability, migration, and invasion of EGI-1 cholangiocarcinoma cellsin vitro, as shown in Figure 3.

    The viability of EGI-1 cells decreased following incubation with GEM or CIS in a dose-dependent manner, and the half-maximal inhibitory concentration (IC50) was 4.625 μg/mL for GEM and 5.933 μg/mL for CIS (Figure 3A). We initially set the drugloading ratio at 1:1 due to the close IC50of these two drugs. Then, we prepared 4 types of polymer films containing different drug compositions (PLCL-0, PLCL-GEM, PLCLCIS, and PLCL-G&C) at 4 drug-loading ratios (5%, 10%, 15%, and 20%). The effect of drug-released media from the first 24 h in the polymer films on the proliferation of EGI-1 cells was tested (Figure 3B). The growth inhibition of EGI-1 cells increased in a loading ratio-dependent manner, and GEM and CIS-coloaded films caused significantly more growth inhibition than single-drug-loaded films (P< 0.001). To ensure inhibitory efficiency and reduce the side effects and drug dose, we set the initial inhibition rate of coloaded film to > 80% as a standard and assumed that a drugloading ratio of 10% might be ideal for further experiments.

    We continuously tested the antitumor effect of the drug release solution from polymer films loaded with 10% drugs on EGI-1 cells for 30 d (Figure 3C). During the observation period, the single-drug-loaded films had a certain inhibitory effect in the early stage, and the effects of PLCL-GEM were stronger than those of PLCL-CIS. However, over time, the effect of PLCL-GEM decreased beginning on day 10 and diminished significantly in the later period; the effect of PLCL-CIS was relatively weak, but it was maintained to some extent and decreased gradually without a significant fall peak in the middle and later stages. This was consistent with the release property of GEM and CIS from the polymer film. The PLCL-GC polymer film exhibited excellent inhibitory capability due to mutual compensation for dual drug release: It showed a stronger effect in the early stage than the single-drug-loaded polymer film that was maintained appropriately in the later stage. The inhibition rate was approximately 30% at the end of the observation period. Therefore, we believe that the continuous release and cumulative effect of the coloaded drugs ensure that this novel DES plays an ideal role in inhibiting tumor cell proliferation.

    We then studied the effects of drug-released media from PLCL-10% GC on the viability, migration, and invasion of EGI-1 cells at specific time points (day 1, 8, 15, 22, and 29; every other week) (Figure 3D). The viability (Figure 3D-a), migration (Figure 3D-b), and invasion (Figure 3D-c) of EGI-1 cells were inhibited by incubation with the released GEM and CIS from the nanofilms during the 30-d drug release period. All the effects were relatively strong in the early phase and then decreased gradually but were still maintained in the later period. These results indicate that the viability inhibition, anti-migration, and anti-invasion capacities of the loaded GEM and CIS from this novel DES are maintained during the drug release period.

    Antitumor activity of PLCL-GEM and CIS nanofilms in an animal tumor xenograft model

    Figure 4 Antitumor activity of drug-loaded nanofilms against subcutaneous tumor xenografts in nude mice in vivo. A: Image of subcutaneous tumors from nude mice after drug-loaded nanofilm implantation for 4 wk; B: Changes in tumor volume; C: Changes in body weight; and D: (a) HE staining (magnification × 200, scale bar 100 μm), immunohistochemical analysis of p53 upregulated modulator of apoptosis and cleaved caspase-3 (×400, scale bar 50 μm), and terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling staining (× 200, scale bar 50 μm) in subcutaneous tumor tissues; (b-d) Statistical analysis results: Quantification of (b) p53 upregulated modulator of apoptosis-positive cell numbers, (c) cleaved caspase-3-positive cell numbers, and terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling-positive cell proportion in subcutaneous tumor tissues. dP < 0.001 vs control (n = 6 mice per group). CIS: Cisplatin; GEM: Gemcitabine; HE: Hematoxylin and eosin; PLCL: Poly L-lactide-caprolactone; PLCL-0: Non-drug-loaded PLCL nanofilm; PLCL-CIS: PLCL nanofilm loaded with CIS; PLCL-GEM: PLCL nanofilm loaded with GEM; PLCL-GC: PLCL nanofilm loaded with both GEM and CIS; PUMA: p53 upregulated modulator of apoptosis; TUNEL: Terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling.

    We used an animal tumor xenograft model to study the anticancer activity of the drugloaded nanofilmsin vivo. Tumor mass from nude mice after implantation of different nanofilms for 28 d is shown in Figure 4A. The tumor sizes in the drug-loaded groups were visually smaller than those in the unloaded and control groups. All drug-loaded films gradually inhibited tumor growth, while PLCL-GC exerted the most ideal suppression effect according to the tumor growth curve (Figure 4B). In addition, tumor growth was partially inhibited in the PLCL-unloaded film group compared to that in the sham-operated group. This observation was probably due to the suppression effect of the nanofilm on vascular reconstruction and contact growth inhibition, which made tumor proliferation relatively limited.

    The weight change curves of the PLCL-unloaded group and the sham-operated group were similar, with no significant difference (P> 0.05). However, varying degrees of weight loss were observed in the drug-loaded groups during the initial period (Figure 4C). The PLCL-GEM nanofilm-implanted group experienced faster weight recovery than the other two groups, and weight recovery steadily increased, consistent with that observed in the control group. The PLCL-GC group seemed to lose the most body weight but still recovered and gained extra body weight at the end of the observation period.

    The weight loss of experimental animals might be caused by the side effects of chemotherapeutics. Due to the relatively large ratio of the nanofilm area to the body surface and the numerous vascular networks on the backs of nude mice, drugs can be easily absorbed and transferred to the whole body, causing toxicity similar to that observed with systemic chemotherapy. Thus, the weight loss of dual-loaded nanofilms was more significant than that of single-drug-loaded nanofilms.

    HE staining of tumor tissues showed reduced pathological karyokinesis and collagen fibroplasia in the drug-loaded groups (Figure 4D-a). The expression of apoptosis-related proteins, such as PUMA (Figure 4D-b) and cleaved caspase-3 (Figure 4D-c), and the number of TUNEL-positive cells (Figure 4D-d) in tumor tissues were all increased with the implantation of drug-loaded nanofilms, indicating that the suppression of tumor growth might be due to the activation of apoptosis-related molecular signals.

    All these results suggest that the drug-loaded nanofilms efficiently exert their antitumor effects in mouse tumor xenograftsin vivo, and the dual-loaded nanofilm was superior to the single-drug-loaded nanofilm.

    Feasibility and safety in the porcine biliary tract

    All stents were successfully placed in porcine biliary tracts without procedure-related complications. Cholangiography confirmed the stent position and patency in the CBD (Figure 5A-b). One case of incisional hernia occurred in the PLCL-0 stent group. No perforation, cholangitis, stent migration, or occlusion occurred in any group, and all porcine survived until euthanization for histopathological analysis 4 wk after stent placement.

    Serum ALT, AST, γ-GT, and amylase levels were elevated, with mild to moderate abnormal levels (< 3-5 upper limit of normal, ULN) during the first week after stent placement, mainly due to the surgical procedure and biliary stricture. All these parameters gradually returned to normal after 4 wk (Supplementary material Table 1, available online), and no differences were observed between groups (P> 0.05 for all).

    Figure 5 Safety evaluation of different drug-eluting biliary stents in a porcine model. A: (a) Critical surgical step necessary to place a stent into the porcine CBD; the stent was sutured on the CBD wall carefully when closing the CBD to avoid stent migration; (b) cholangiogram after stent placement; the pentacle marks the location of the stent; (c) macroscopic appearance of the CBD after animals were sacrificed; all the stents were still in the CBD and had not migrated; B: HE staining of the CBD (magnification ×200, scale bar 100 μm), liver, kidney, and duodenum (× 100, scale bar 200 μm) 30 d after placement of different drug-eluting biliary stents; C: Masson trichrome staining of the CBD 30 d after placement of different drug-eluting biliary stents (× 200, scale bar 100 μm). CBD: Common bile duct; CIS: Cisplatin; GEM: Gemcitabine; PLCL: Poly-L-lactide-caprolactone; PLCL-0: Non-drug-loaded PLCL nanofilm; PLCL-CIS: PLCL nanofilm loaded with CIS; PLCL-GEM: PLCL nanofilm loaded with GEM; PLCL-GC: PLCL nanofilm loaded with both GEM and CIS.

    The gross appearance of the bile duct mucosa from the 5 groups was similar, and no ulceration, perforation, or necrosis was observed (Figure 5A-c). In addition, no apparent luminal dilation, wall thinning, or mucosal hyperplasia was observed along the bile duct segment that had been stented.

    Microscopically, epithelial layer thickness was more obvious in the stent-implanted groups than in the sham-operated group, with a multilayered epithelium instead of a normal single layer of cuboidal epithelium, which might be a chronic adaptive change to the compression and dilation of the stent. However, no significant difference was observed between the stented groups (Figure 5B, Table 1). The CBD wall of the stented segments presented mild inflammation in the non-drug-loaded group, and drugloaded components seemed to increase the degree of inflammatory cell infiltration. In addition, cisplatin in the membrane was associated with inflammatory reactions in the mucosa and submucosa (Figure 5B, Table 1). Masson trichrome staining revealed a similar extent of fibrotic reactions without fibromuscular wall thickening or collagen fiber homogenization in the submucosal layer of stented segments in all groups, suggesting that fibrotic reactions are not dependent on drug-loaded components (Figure 5C). No granulation, atrophy or necrosis was observed in any group. In addition, no histological changes in the duodenum, liver, or kidney were observed in any group (Figure 5B).

    In conclusion,in vivoexperiments confirmed that the DES has good safety and biocompatibility in the normal porcine biliary tract.

    DISCUSSION

    Currently, ECC is rarely curable and is associated with a poor prognosis. The therapeutic resistance of ECC is mainly due to its highly desmoplastic nature, rich tumor microenvironment, and profound genetic heterogeneity[22]. Although a few breakthroughs and progress in the treatment of ECC have been made since comprehensive cancer therapies, such as targeted therapy and immunotherapy, the mortality has not been significantly decreased. According to the newest NCCN guidelines, the primary therapeutic strategy for unresectable ECC is still biliary drainage, if indicated GEM/CIS combination therapy is also used[23]. However, endoscopic stent placement for the palliation of malignant biliary obstruction is associated with a high failure rate since reocclusion is common after stent implantation[5,8]. In addition, patients under systemic chemotherapy with GEM/CIS tend to suffer from toxic side effects such as myelosuppression, digestive tract reactions, hepatotoxicity, and nephrotoxicity[17-19]. Therefore, a new concept of a “therapeutic stent” was proposed to achieve local antitumor therapy for ECC. First, local chemotherapy may maximize the drug concentration in the tumor microenvironment and reduce toxicity on nontarget organs through systemic distribution[8]. It may also reduce the required drug dose and thus save costs. Second, the local inhibition of tumor proliferation may prevent stent stenosis or obstruction from tumor ingrowth or epithelial overgrowth in an advanced stage[7]. This may result in a prolonged patency time and biliary drainage to reduce the risk of cholangitis, progressive jaundice, or even biliary sepsis. We propose that this therapeutic stent will help improve the survival and quality of life of ECC patients.

    DES is a promising therapy, and its effective design realizes the dual function of biliary drainage and local chemotherapy in malignant biliary obstructions. Relevant studies have been published, including those on esophageal cancer[24,25], colorectal cancer[26,27], and bile duct cancer[6,9-12,15,28-30]. Most of the biliary stents used in earlier studies were paclitaxel-eluted stents, and there seemed to be no improvement in the duration of stent patency or survival time compared to unloaded stents in several prospective pilot studies[10,12]. Possible reasons for these findings may be nonoptimal medications and poor drug release to maintain sufficient local antitumor activity. However, these studies still demonstrated the safety and feasibility of the application of DESs in patients with ECC. DESs loaded with other antitumor agents, including gemcitabine[29], sorafenib[15], and vorinostat[30], have also been investigated for safety and efficacy in malignant biliary obstruction. These DESs were all single-drug-loaded stents with a simple design and lacked complete serialin vitroandin vivodata. Our study was the first to apply dual chemotherapeutic medications to DESs for the management of ECC with a relatively complete preclinical evaluation.

    The debate concerning the choice between fully covered self-expanding biliary metal stents (FCSEMSs) and uncovered self-expandable metal stents in patients with malignant biliary stricture has been protracted in the medical literature and is still ongoing[31]. Some researchers demonstrated that covered stents were associated with increased rates of migration and cholecystitis[32,33], while others reported no statistically significant difference between them[34-36]. Since no official guideline or conclusive evidence has been established so far, the stent type should be selected on an individualized basis. Notably, inflammatory cell infiltration and mucosal hyperplasiawere reported to be more obvious in uncovered stents than in covered stents[37]. In DESs with a partially covered design (due to concerns associated with stent migration), these histological changes were severe in the biliary mucosa in contact with the bare ends of the stent[9]. Of note, Wang and colleagues developed partially covered nitinol stents loaded with 5-fluorouracil or paclitaxel for esophageal cancer and found severe tissue responses, including inflammation, ulceration, and granulation, at the bare ends compared to the drug-loaded part in porcine esophageal tissues[25]. Since partially covered stents have not yet been proven to be effective in the prevention of stent migration for malignant biliary strictures and still need to be further evaluated in clinical trials[38,39], in our study, we used a fully covered stent design to alleviate tissue responses.

    Table 1 Epithelial layer thickness and inflammation in the common bile duct after stent placement

    We also made several improvements in the design of our DES based on the experience of the initial paclitaxel-eluted stents in the early stage. First, we chose the first-line chemotherapeutic medications GEM plus CIS as the loaded drugs on the assumption that dual drugs would be superior to single drugs in local antitumor activity. Second, we used the PTFE membrane as the inner blocker to (1) ensure unidirectional drug release to the tumor tissue side to avoid fluctuation release and drug loss by bile flow; and (2) prevent membrane degradation materials from clogging and occluding the stent lumen[11]. Third, we added a PLCL outer layer without drugs to prevent an initial burst[29]. According to the drug release curve, we successfully obtained a stable, continuous, and long-term release of GEM/CIS without an apparent initial burst, which was essential to sustain pharmacological effects without severe toxicity.

    The results of thein vitrocell experiments andin vivotumor xenograft model confirmed the antitumor activity of the drug-loaded nanofilms, and the dual-drugloaded films showed a much better effect than the single-drug-loaded films. Interestingly, the antitumor effect of the single-drug-loaded nanofilms seemed to differin vitroandin vivo: the PLCL-GEM nanofilm showed a stronger tumor suppression effect in the cell experiment, while the PLCL-CIS nanofilm inhibited tumor growth more potently in the tumor xenograft model. Possible reasons for these observations might be the differences in experimental parameters and drug release propertiesin vitroandin vivo. We used drug-released media to evaluate antitumor activityin vitro, and the effective drug concentration of gemcitabine was higher than that of cisplatin in the early observation period due to differences in solubility. Moreover, the incubation of drug-released media with EGI-1 cells was evaluated as a short-term effect. However, in thein vivonude mouse tumor xenograft experiment, drug release was realized through direct contact together with diffusion to tumor tissue rather than simple dissolution, and the change in tumor xenografts reflected the long-term cumulative effect. Thus, the synergistic effect of dual drug loading was clarified theoretically and practically: the initial release of GEM played a dominant role in the early stage, and the compensatory release of CIS subsequently ensured the maintenance f the long-term antitumor effect.

    Serological analysisin vivoshowed that the WBC count, ALT, AST, γ-GT, and amylase levels were elevated to varying degrees: The WBC count and amylase level were only mildly increased, while the ALT, AST, and γ-GT levels were increased moderately (3-5 × upper limit of normal). These changes were associated with transient hepatic damage secondary to the surgical procedure and gradually returned to baseline during the follow-up period in all animals[29]. No significant differences were observed between the different stent type groups, which indicated that the serological change was not drug related or dose-dependent but rather procedure related.

    Previous studies have examined the histologic influence of FCSEMS[40]and chemotherapeutic drug-eluting stent[6,9,11,29]placement in the bile duct, and these stents have been reported to cause an inflammatory reaction[29,40], mucosal hyperplasia[9], and fibrosis[11]. In our study, no significant differences in inflammation, fibrosis, or collagenous reactions were observed between the different stent type groups. Superficial mucosal erosion with a denuded cuboidal epithelium is common for epithelial injury after stent removal[40]. Bakhruet al[40]reported that 80% of the porcine biliary tract developed superficial mucosal erosion after the removal of temporarily placed FCSEMSs[40], and we observed a similar change in our stented groups. Moreover, epithelial layer thickness secondary to reactive hyperplasia was common and reasonable. However, no significant complications, such as lumen stenosis, occlusion, ulceration, necrosis, or perforation, were observed in any of the animals during stent implantation. Taken together, these findings of laboratory parameters and histological changes indicate that the implantation of this PLCL-GEM and CIS DES in a normal porcine bile duct is acceptable in terms of safety and feasibility.

    However, our study still has several limitations. First, we tested the drug release property onlyin vitro; therefore, relevantin vivodata are lacking. Further studies should include drug distribution in the plasma and major organs after stent implantation. Second, we established only mouse xenograft models to study the antitumor activity of this newly designed stentin vivo; the results might not be representative of the real effectin vivosince subcutaneous tumor xenografts cannot accurately model the polymicrobial and complicated tumor microenvironment of the biliary tract. However, the corresponding large animal model of ECC in the porcine or canine biliary tract is still not available. Third, the small sample size decreased the statistical power of our results, and our study lasted for only 4 wk, which might not be sufficient for evaluation of the long-term effects after stent insertion. Thus, a larger sample size and longer observation period are needed to further assess safety and feasibilityin vivoand to obtain reliable preclinical outcomes. Finally, we used the suture strategy, which does not correspond to clinical practice, to decrease the rates of migration after stent insertion. More reasonable modifications can be applied for antimigration, including a modi?ed con?guration with anchoring ?ns, ?ared ends, an anchoring ?ap, or a larger diameter[41].

    In conclusion, we designed a novel biliary stent coated with antitumor agents (GEM and CIS), and we preliminarily confirmed its sustained local drug release and potent antitumor activityin vitroandin vivo. We anticipate that this new DES can be an alternative strategy as a fundamental component of palliative management for ECC patients and may help improve their survival and quality of life.

    ARTICLE HIGHLIGHTS

    Research background

    Currently, extrahepatic cholangiocarcinoma (ECC) is rarely curable and associated with a poor prognosis. Effective endoscopic management is fundamental for ECC at an unresectable stage; however, the current biliary stents used clinically have shown no antitumor effect and are associated with high failure rates due to reocclusion after stent implantation.

    Research motivation

    DES is a new therapeutic concept for the management of ECC and may realize a combination of local chemotherapy and biliary drainage to prolong stent patency and improve prognosis. However, there have been only limited studies thus far, and all of them were only single-drug-loaded stents with a simple design and unsatisfactory efficacy. Our study was motivated by the need to develop a novel DES that can improve palliative endoscopic management for ECC. In addition, we have accumulated rich experience with sodium cholate and disodium ethylene diamine tetraacetic acid-eluting stents for the dissolution of bile duct stones in our previous studies, which aided in our current study.

    Research objectives

    Our study aimed to develop a novel DES coated with gemcitabine (GEM) and cisplatin (CIS)-loaded PLCL nanofilms that can maintain the continuous and long-term release of antitumor agents in the bile duct locally to inhibit tumor growth and reduce systemic toxicity.

    Research methods

    In our study, four different DESs were manufactured by the mixed electrospinning method, namely, bare-loaded, single-drug-loaded (GEM or CIS), and dual-drugloaded (GEM and CIS) stents, with four drug-loading ratios (5%, 10%, 15%, and 20%). The drug release property, antitumor activity in the ECC cell line and mouse xenograft model, and biocompatibility in the normal porcine bile duct were evaluated to confirm the feasibility and efficacy of this novel DES for ECC.

    Research results

    We identified 10% as the appropriate drug-loading ratio based on the drug release property and inhibition efficiency. Further investigation indicated that these drugloaded nanofilms exert ideal antitumor activity and good biosecurity.

    Research conclusion

    This novel PLCL-GEM and CIS-eluting stent maintains continuous, stable drug release locally and exerts potent antitumor activityin vitroandin vivo. Therefore, it might be considered an alternative strategy for the palliative therapy of ECC patients.

    Research perspectives

    Future studies comparing DESs and conventional systemic chemotherapy may provide more reliable evidence for the preclinical evaluation of this novel stent for the management of ECC. With development and progress in multidisciplinary therapy for cancer, it is also worth investigating the benefit of replacing systemic chemotherapy with DESs together with targeted therapy and immunotherapy in the future.

    亚洲综合色惰| 国产成人一区二区在线| 国产成人免费无遮挡视频| 欧美精品人与动牲交sv欧美| 久久亚洲国产成人精品v| 亚洲精品456在线播放app| 人人妻人人添人人爽欧美一区卜 | 日韩在线高清观看一区二区三区| 亚洲综合精品二区| 国产精品三级大全| 欧美日韩在线观看h| 国产av码专区亚洲av| 成人一区二区视频在线观看| 51国产日韩欧美| 舔av片在线| 美女国产视频在线观看| 男女边摸边吃奶| 一个人看的www免费观看视频| 最近最新中文字幕大全电影3| 久久精品久久久久久久性| 欧美xxxx黑人xx丫x性爽| 大码成人一级视频| 永久免费av网站大全| 国产欧美亚洲国产| 国产精品不卡视频一区二区| 尤物成人国产欧美一区二区三区| 好男人视频免费观看在线| 亚洲精品国产成人久久av| 一区在线观看完整版| 成年美女黄网站色视频大全免费 | 亚洲美女视频黄频| 身体一侧抽搐| 一个人看视频在线观看www免费| 老熟女久久久| 日本黄色片子视频| 一级毛片我不卡| 久久久国产一区二区| av免费观看日本| 全区人妻精品视频| 欧美人与善性xxx| 丝袜喷水一区| 极品教师在线视频| 中文乱码字字幕精品一区二区三区| 国产精品精品国产色婷婷| 18禁裸乳无遮挡动漫免费视频| 在线观看av片永久免费下载| 黄色配什么色好看| 成人综合一区亚洲| 免费看日本二区| 男人和女人高潮做爰伦理| 色视频在线一区二区三区| 国产精品三级大全| 亚洲怡红院男人天堂| 九九在线视频观看精品| 国产色爽女视频免费观看| 在现免费观看毛片| 噜噜噜噜噜久久久久久91| 亚洲一级一片aⅴ在线观看| 夜夜看夜夜爽夜夜摸| 日日摸夜夜添夜夜添av毛片| 国产精品蜜桃在线观看| 中文字幕精品免费在线观看视频 | 少妇人妻久久综合中文| 内射极品少妇av片p| 精品99又大又爽又粗少妇毛片| 在线免费十八禁| 18禁在线播放成人免费| 99热国产这里只有精品6| 亚洲激情五月婷婷啪啪| 欧美日韩一区二区视频在线观看视频在线| 国产又色又爽无遮挡免| 直男gayav资源| 亚洲国产成人一精品久久久| 熟女人妻精品中文字幕| 性色avwww在线观看| 深爱激情五月婷婷| 99热国产这里只有精品6| 亚洲一区二区三区欧美精品| 午夜福利在线观看免费完整高清在| 蜜桃在线观看..| 日日啪夜夜爽| 中文字幕免费在线视频6| 99九九线精品视频在线观看视频| 少妇人妻久久综合中文| 欧美bdsm另类| 成人黄色视频免费在线看| 亚洲av中文av极速乱| 国产有黄有色有爽视频| 日日摸夜夜添夜夜添av毛片| 另类亚洲欧美激情| 久久国产精品男人的天堂亚洲 | 国产一级毛片在线| 国产黄色视频一区二区在线观看| 国产探花极品一区二区| 国产精品精品国产色婷婷| 亚洲自偷自拍三级| 欧美bdsm另类| 少妇人妻一区二区三区视频| 日本与韩国留学比较| 亚洲精品aⅴ在线观看| 黑丝袜美女国产一区| 成人高潮视频无遮挡免费网站| 人人妻人人爽人人添夜夜欢视频 | 永久网站在线| 精品国产露脸久久av麻豆| av.在线天堂| 交换朋友夫妻互换小说| 精品熟女少妇av免费看| 中文在线观看免费www的网站| 久久久久国产精品人妻一区二区| 精品久久久精品久久久| av国产精品久久久久影院| 色视频在线一区二区三区| 男男h啪啪无遮挡| 大片免费播放器 马上看| 国产片特级美女逼逼视频| 麻豆成人午夜福利视频| 成人无遮挡网站| 嫩草影院入口| 精品少妇久久久久久888优播| 久久青草综合色| 91精品国产国语对白视频| 久久综合国产亚洲精品| 狂野欧美激情性xxxx在线观看| 日韩av免费高清视频| 九色成人免费人妻av| 我要看日韩黄色一级片| 九色成人免费人妻av| 91在线精品国自产拍蜜月| 综合色丁香网| 夫妻午夜视频| 国产精品女同一区二区软件| av国产精品久久久久影院| 一边亲一边摸免费视频| 十分钟在线观看高清视频www | 精品久久久噜噜| 免费人成在线观看视频色| 国产成人精品一,二区| 亚洲国产毛片av蜜桃av| 欧美97在线视频| 久久婷婷青草| 亚洲丝袜综合中文字幕| 欧美一级a爱片免费观看看| 国产在线男女| 国产在线男女| 成人亚洲精品一区在线观看 | 亚洲精品日韩在线中文字幕| 91午夜精品亚洲一区二区三区| 最黄视频免费看| 91aial.com中文字幕在线观看| 街头女战士在线观看网站| 精品一区二区免费观看| 国产成人91sexporn| 丰满人妻一区二区三区视频av| 国产成人免费观看mmmm| 国产黄频视频在线观看| 亚洲欧美日韩无卡精品| 最黄视频免费看| 99久久精品热视频| 美女国产视频在线观看| 久久久久久久久大av| 亚洲国产欧美在线一区| av国产免费在线观看| 少妇被粗大猛烈的视频| 精品一区二区免费观看| 国产欧美另类精品又又久久亚洲欧美| 大码成人一级视频| 亚洲国产欧美人成| 成人漫画全彩无遮挡| 女人十人毛片免费观看3o分钟| 我要看日韩黄色一级片| 亚洲高清免费不卡视频| 18禁裸乳无遮挡免费网站照片| 人人妻人人添人人爽欧美一区卜 | 2018国产大陆天天弄谢| 久久久久视频综合| 在线观看三级黄色| 国产一区二区在线观看日韩| 日本wwww免费看| 国产 一区精品| 少妇丰满av| 日韩制服骚丝袜av| 成人国产麻豆网| 日本vs欧美在线观看视频 | 久久精品人妻少妇| 午夜福利在线在线| www.色视频.com| 欧美性感艳星| 国产黄片视频在线免费观看| 性色avwww在线观看| 色婷婷久久久亚洲欧美| 久久精品国产亚洲网站| 国产日韩欧美亚洲二区| 亚洲av在线观看美女高潮| 国产淫语在线视频| 男女无遮挡免费网站观看| 久久这里有精品视频免费| 亚洲欧美成人精品一区二区| av视频免费观看在线观看| 91狼人影院| 精品少妇黑人巨大在线播放| 日日摸夜夜添夜夜添av毛片| 精品国产一区二区三区久久久樱花 | 狂野欧美激情性xxxx在线观看| 亚洲精品国产成人久久av| 超碰av人人做人人爽久久| 能在线免费看毛片的网站| 99热6这里只有精品| 妹子高潮喷水视频| 精品亚洲成国产av| 少妇的逼水好多| 国产精品久久久久久久电影| 在线观看免费日韩欧美大片 | 91精品伊人久久大香线蕉| 在线观看国产h片| 亚洲精品国产av成人精品| 最近的中文字幕免费完整| 丝瓜视频免费看黄片| 欧美高清成人免费视频www| 三级经典国产精品| 大话2 男鬼变身卡| 欧美日韩精品成人综合77777| 久久久久视频综合| 天美传媒精品一区二区| 成年人午夜在线观看视频| 在线免费观看不下载黄p国产| 国产91av在线免费观看| 在线观看人妻少妇| 国产在线男女| 亚洲性久久影院| 99精国产麻豆久久婷婷| 日韩av不卡免费在线播放| 国产亚洲5aaaaa淫片| 一级片'在线观看视频| 欧美一区二区亚洲| 能在线免费看毛片的网站| 少妇熟女欧美另类| 国产一区有黄有色的免费视频| 国产毛片在线视频| 久久精品国产亚洲av涩爱| 九草在线视频观看| 哪个播放器可以免费观看大片| 男女国产视频网站| 精品久久久久久久末码| 亚洲av不卡在线观看| 日韩一区二区视频免费看| 国产毛片在线视频| 2022亚洲国产成人精品| 亚洲精品日韩av片在线观看| 十分钟在线观看高清视频www | 亚洲第一区二区三区不卡| 天天躁夜夜躁狠狠久久av| 国产精品秋霞免费鲁丝片| 亚洲av男天堂| 青青草视频在线视频观看| 免费观看的影片在线观看| 久久人人爽人人片av| 久久久a久久爽久久v久久| 亚洲无线观看免费| 国产免费一级a男人的天堂| av在线观看视频网站免费| 五月玫瑰六月丁香| av国产精品久久久久影院| 国产中年淑女户外野战色| 老师上课跳d突然被开到最大视频| 国产成人一区二区在线| 国产熟女欧美一区二区| 日本av免费视频播放| 一级a做视频免费观看| 国产成人a∨麻豆精品| 国产 精品1| 日日啪夜夜爽| 日韩国内少妇激情av| 日日啪夜夜撸| 中文精品一卡2卡3卡4更新| 久久综合国产亚洲精品| 久久久午夜欧美精品| 亚州av有码| 精品久久久久久久末码| 国产精品蜜桃在线观看| 成人午夜精彩视频在线观看| 午夜福利网站1000一区二区三区| 亚洲av.av天堂| 亚洲成人手机| 久久久久久人妻| 97超碰精品成人国产| 欧美三级亚洲精品| 精品久久久久久电影网| 亚洲,一卡二卡三卡| 少妇熟女欧美另类| 午夜免费观看性视频| 成年美女黄网站色视频大全免费 | 六月丁香七月| 少妇 在线观看| 久久精品熟女亚洲av麻豆精品| 国产高清不卡午夜福利| 哪个播放器可以免费观看大片| 我要看日韩黄色一级片| 日韩亚洲欧美综合| 亚洲人成网站高清观看| 成人亚洲欧美一区二区av| 最新中文字幕久久久久| 久久97久久精品| 三级国产精品片| 新久久久久国产一级毛片| 国产精品一区二区三区四区免费观看| 少妇人妻一区二区三区视频| 国产欧美另类精品又又久久亚洲欧美| 国产免费一区二区三区四区乱码| 亚洲国产成人一精品久久久| 日本黄色日本黄色录像| av播播在线观看一区| 国精品久久久久久国模美| 中文字幕免费在线视频6| 久久久久久久久久成人| 男女边摸边吃奶| 日韩中文字幕视频在线看片 | 亚洲第一av免费看| 女人久久www免费人成看片| 婷婷色综合大香蕉| 免费观看性生交大片5| 亚洲精品国产av成人精品| av在线app专区| 国产熟女欧美一区二区| 国产一区亚洲一区在线观看| 我要看黄色一级片免费的| 亚洲国产精品国产精品| 国产女主播在线喷水免费视频网站| 精品一区在线观看国产| 夜夜骑夜夜射夜夜干| 99久久人妻综合| 岛国毛片在线播放| 一区二区av电影网| 亚洲婷婷狠狠爱综合网| 国产久久久一区二区三区| 日韩国内少妇激情av| 亚洲真实伦在线观看| 国产视频首页在线观看| 国产美女午夜福利| 国产色婷婷99| 午夜福利在线观看免费完整高清在| 免费不卡的大黄色大毛片视频在线观看| 少妇猛男粗大的猛烈进出视频| 亚洲精品国产av蜜桃| 国产伦理片在线播放av一区| 亚洲精品乱码久久久久久按摩| 欧美精品国产亚洲| 中文乱码字字幕精品一区二区三区| 亚洲美女搞黄在线观看| 亚洲国产高清在线一区二区三| 日本av手机在线免费观看| 直男gayav资源| 2022亚洲国产成人精品| 久久国产亚洲av麻豆专区| 另类亚洲欧美激情| 亚洲av成人精品一二三区| av不卡在线播放| 久久亚洲国产成人精品v| 午夜福利在线在线| 日日摸夜夜添夜夜爱| 新久久久久国产一级毛片| 在线观看免费日韩欧美大片 | 中文字幕久久专区| 婷婷色综合大香蕉| 熟女人妻精品中文字幕| 伊人久久精品亚洲午夜| 亚洲国产av新网站| 国产在视频线精品| 欧美激情国产日韩精品一区| 草草在线视频免费看| 日韩亚洲欧美综合| 人妻 亚洲 视频| 亚洲精品亚洲一区二区| 国国产精品蜜臀av免费| 久久精品夜色国产| 久久毛片免费看一区二区三区| 亚洲一区二区三区欧美精品| av在线播放精品| 如何舔出高潮| 欧美区成人在线视频| 色哟哟·www| 国产中年淑女户外野战色| 午夜免费观看性视频| 日韩人妻高清精品专区| 久久人人爽人人爽人人片va| 建设人人有责人人尽责人人享有的 | 亚洲欧美日韩卡通动漫| 国产精品蜜桃在线观看| 精品国产露脸久久av麻豆| 多毛熟女@视频| 91精品国产九色| 亚洲第一区二区三区不卡| 国产亚洲最大av| 久久精品国产a三级三级三级| 久久人妻熟女aⅴ| 我的女老师完整版在线观看| 2021少妇久久久久久久久久久| 国产色婷婷99| 亚洲精品日韩在线中文字幕| 欧美日韩视频高清一区二区三区二| 久久99热6这里只有精品| 国产一区二区三区综合在线观看 | 精品久久国产蜜桃| 在线免费观看不下载黄p国产| 国产精品99久久久久久久久| 99热国产这里只有精品6| 精品久久久久久久末码| 国产色爽女视频免费观看| 91久久精品电影网| 亚洲精品国产色婷婷电影| 超碰97精品在线观看| 精品少妇黑人巨大在线播放| 大码成人一级视频| 性色av一级| 在线天堂最新版资源| 男女边吃奶边做爰视频| 一级av片app| 欧美日韩一区二区视频在线观看视频在线| 欧美精品国产亚洲| 久久精品夜色国产| 国产伦在线观看视频一区| 国产一区二区在线观看日韩| 欧美xxxx黑人xx丫x性爽| 国产免费又黄又爽又色| 亚洲真实伦在线观看| 18禁在线无遮挡免费观看视频| 在线观看一区二区三区激情| 免费人妻精品一区二区三区视频| 少妇猛男粗大的猛烈进出视频| 精品久久久噜噜| 亚洲激情五月婷婷啪啪| 91久久精品国产一区二区成人| 国产成人精品一,二区| 亚洲精品久久久久久婷婷小说| 校园人妻丝袜中文字幕| 日日啪夜夜爽| 欧美精品一区二区大全| 欧美一区二区亚洲| 大又大粗又爽又黄少妇毛片口| 亚洲欧美日韩无卡精品| 高清欧美精品videossex| 18+在线观看网站| 久久久成人免费电影| 少妇人妻精品综合一区二区| 精品国产一区二区三区久久久樱花 | 男的添女的下面高潮视频| 在线观看美女被高潮喷水网站| 免费少妇av软件| 在线观看一区二区三区| 狂野欧美白嫩少妇大欣赏| 看免费成人av毛片| 国产亚洲91精品色在线| 亚洲精品中文字幕在线视频 | 日韩一区二区三区影片| 欧美最新免费一区二区三区| 亚洲欧美精品专区久久| 国产精品女同一区二区软件| 亚洲图色成人| 在线观看av片永久免费下载| 国产黄片视频在线免费观看| av在线老鸭窝| 国产黄色免费在线视频| 亚洲色图综合在线观看| 国产成人a区在线观看| 亚洲精品亚洲一区二区| 亚洲aⅴ乱码一区二区在线播放| 成人美女网站在线观看视频| 国产精品无大码| 国内精品宾馆在线| 麻豆成人av视频| 亚洲一级一片aⅴ在线观看| 国产乱来视频区| 国产av码专区亚洲av| 在线观看国产h片| 又爽又黄a免费视频| 亚洲av欧美aⅴ国产| 日日摸夜夜添夜夜爱| 久久久精品免费免费高清| 日韩精品有码人妻一区| 国产美女午夜福利| 久久女婷五月综合色啪小说| 亚洲精品国产色婷婷电影| 伊人久久国产一区二区| 午夜福利在线在线| 久久午夜福利片| 欧美日本视频| 久久久久久伊人网av| 国产69精品久久久久777片| 免费观看av网站的网址| 观看美女的网站| 久久久久久久亚洲中文字幕| 国产精品福利在线免费观看| 免费观看的影片在线观看| 在线精品无人区一区二区三 | 欧美极品一区二区三区四区| av网站免费在线观看视频| 毛片一级片免费看久久久久| 午夜免费男女啪啪视频观看| 亚洲av.av天堂| 亚洲精品中文字幕在线视频 | 亚洲av在线观看美女高潮| 日产精品乱码卡一卡2卡三| 欧美成人一区二区免费高清观看| 欧美+日韩+精品| 777米奇影视久久| 欧美成人午夜免费资源| 亚洲精品日韩在线中文字幕| 嫩草影院入口| 中国美白少妇内射xxxbb| 亚洲国产欧美在线一区| 午夜精品国产一区二区电影| 亚洲激情五月婷婷啪啪| 最近手机中文字幕大全| 网址你懂的国产日韩在线| 搡老乐熟女国产| 亚洲三级黄色毛片| 精品一区二区免费观看| 久久精品久久久久久久性| 大话2 男鬼变身卡| videossex国产| 久久久久久久久久久免费av| 国精品久久久久久国模美| 久久久久久久久久成人| 国产精品一区二区在线不卡| 大又大粗又爽又黄少妇毛片口| 少妇人妻久久综合中文| 中文字幕亚洲精品专区| 亚洲欧美日韩无卡精品| 免费在线观看成人毛片| 亚洲精品aⅴ在线观看| 亚洲精品日本国产第一区| 在线天堂最新版资源| 天天躁日日操中文字幕| 大香蕉久久网| av国产免费在线观看| 三级国产精品片| 亚洲精品久久久久久婷婷小说| 国产人妻一区二区三区在| 久久人妻熟女aⅴ| 一本久久精品| 国产黄片美女视频| 日本av手机在线免费观看| 亚洲性久久影院| 欧美一区二区亚洲| 久久久久久久久久成人| 欧美日韩视频高清一区二区三区二| 麻豆成人av视频| 国产综合精华液| 国产毛片在线视频| 日韩成人av中文字幕在线观看| 高清视频免费观看一区二区| 国产精品一区二区在线不卡| 国产伦精品一区二区三区四那| 亚州av有码| 在线观看一区二区三区激情| 亚洲av男天堂| 亚洲不卡免费看| 欧美bdsm另类| 嘟嘟电影网在线观看| 自拍偷自拍亚洲精品老妇| 热re99久久精品国产66热6| 国产黄色免费在线视频| 国产精品久久久久久精品电影小说 | 国产免费福利视频在线观看| 毛片女人毛片| 全区人妻精品视频| 丰满少妇做爰视频| 夫妻性生交免费视频一级片| 久久国产亚洲av麻豆专区| 日韩,欧美,国产一区二区三区| av一本久久久久| 久热这里只有精品99| 日韩av免费高清视频| 精品视频人人做人人爽| 亚洲内射少妇av| 青春草视频在线免费观看| 大码成人一级视频| tube8黄色片| 亚洲精品色激情综合| 国产色爽女视频免费观看| 亚洲av.av天堂| 直男gayav资源| 亚洲av成人精品一二三区| 亚洲av在线观看美女高潮| 国产成人91sexporn| 欧美成人午夜免费资源| 免费播放大片免费观看视频在线观看| 热re99久久精品国产66热6| 欧美亚洲 丝袜 人妻 在线| 狂野欧美激情性bbbbbb| 日韩人妻高清精品专区| 人妻少妇偷人精品九色| 午夜福利网站1000一区二区三区| 男人爽女人下面视频在线观看| 午夜日本视频在线| 如何舔出高潮| 美女国产视频在线观看| 夜夜爽夜夜爽视频| 狂野欧美激情性xxxx在线观看| 免费看不卡的av| 毛片一级片免费看久久久久| 在线看a的网站| 麻豆精品久久久久久蜜桃| 亚洲精品自拍成人| 国产无遮挡羞羞视频在线观看| 哪个播放器可以免费观看大片| 中文字幕免费在线视频6| 国内揄拍国产精品人妻在线| 亚洲美女搞黄在线观看| 十分钟在线观看高清视频www | 多毛熟女@视频| 91精品一卡2卡3卡4卡| 亚洲av电影在线观看一区二区三区| 国产精品不卡视频一区二区| 亚洲欧美日韩卡通动漫|